ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT)

CUSIP: H0036K147

Q4 2022 13F Holders as of 31 Dec 2022

Type / Class
Equity / Common Shares, par value CHF 0.08 per share
Shares outstanding
124,261,423
Total 13F shares
38,834,584
Share change
+2,203,827
Total reported value
$149,117,927
Put/Call ratio
145%
Price per share
$3.84
Number of holders
59
Value change
+$3,712,534
Number of buys
33
Number of sells
32

Quarterly Holders Quick Answers

What is CUSIP H0036K147?
CUSIP H0036K147 identifies ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q4 2022

As of 31 Dec 2022, ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) was held by 59 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 38,834,584 shares. The largest 10 holders included Redmile Group, LLC, FMR LLC, MILLENNIUM MANAGEMENT LLC, JPMORGAN CHASE & CO, ALLIANCEBERNSTEIN L.P., GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC, EVENTIDE ASSET MANAGEMENT, LLC, BANK OF AMERICA CORP /DE/, and PRICE T ROWE ASSOCIATES INC /MD/. This page lists 59 institutional shareholders reporting positions in this security for the Q4 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.